Atlas Trials

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Clinical trial NCT05201612 · UNKNOWN

Trial details

NCT number
NCT05201612
Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Colorectal Cancer
Start date
2022-07-07
Primary completion
2024-09-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.